ZBIO Stock Forecast & Price Target

Zenas BioPharma is viewed positively because obexelimab addresses a large and expanding IgG4-RD market, where ZBIO now estimates ~30–40K prevalent US cases, ~25K diagnosed and treated patients, and a ~$4B US commercial opportunity, while only ~1,200 Uplizna patients suggest substantial room for share gain. The company also benefits from a differentiated mechanism versus B-cell depleters, as obexelimab avoids cytotoxic B-cell depletion, steroid toxicity, infusion burden, and the infection risk tied to prolonged depletion, supporting physician interest and potential 47% biologic prescription capture. Near-term catalysts remain supportive, including influenza and SARS-CoV-2 vaccine-response data on October 8 and November 10, plus topline Ph 2 SunStone SLE results in 4Q26 and initial ZB021 healthy volunteer data by YE26.

Zenas BioPharma is a clinical-stage biopharmaceutical company whose outlook is weighed down by heavy dependence on obexelimab, a lead program that may fail to demonstrate efficacy, acceptable dosing intervals, or a clean safety profile in target indications. Clinical or regulatory setbacks could halt development, slow market uptake, or force financing needs higher, while commercial adoption could be pressured by current and future competing therapies. With sales estimates potentially missed and no diversified revenue base evident, the company remains exposed to significant execution risk across development, regulation, and commercialization.